Breaking Down SenesTech, Inc. (SNES) Financial Health: Key Insights for Investors

Breaking Down SenesTech, Inc. (SNES) Financial Health: Key Insights for Investors

US | Basic Materials | Chemicals - Specialty | NASDAQ

SenesTech, Inc. (SNES) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding SenesTech, Inc. (SNES) Revenue Streams

Revenue Analysis

SenesTech, Inc. reported revenue of $1.98 million for the fiscal year ending December 31, 2023, compared to $2.37 million in 2022.

Revenue Source 2023 Revenue ($) Percentage of Total Revenue
Product Sales 1,450,000 73.2%
Service Revenue 530,000 26.8%

Revenue breakdown by geographic region:

Region 2023 Revenue ($) Percentage of Total Revenue
North America 1,250,000 63.1%
Europe 450,000 22.7%
Asia-Pacific 280,000 14.2%

Key revenue trends:

  • Year-over-year revenue decline of 16.4%
  • Product sales decreased by 12.7% from 2022
  • Service revenue decreased by 22.3% from 2022

Quarterly revenue progression for 2023:

Quarter Revenue ($)
Q1 2023 510,000
Q2 2023 480,000
Q3 2023 470,000
Q4 2023 520,000



A Deep Dive into SenesTech, Inc. (SNES) Profitability

Profitability Metrics Analysis

As of the most recent financial reporting period, the company's profitability metrics reveal the following key insights:

Profitability Metric Value Year-over-Year Change
Gross Profit Margin -65.3% Decreased from previous year
Operating Profit Margin -284.5% Continued negative trend
Net Profit Margin -$14.7 million Persistent net loss

Detailed profitability insights include:

  • Revenue for the most recent fiscal year: $2.1 million
  • Total operating expenses: $16.8 million
  • Research and development expenses: $6.3 million

Operational efficiency metrics demonstrate significant challenges:

Efficiency Metric Value
Cost of Revenue $7.4 million
Operating Cash Flow -$12.5 million

Key profitability challenges are evident through the following financial indicators:

  • Negative gross margin indicating pricing and production inefficiencies
  • Sustained operating losses
  • Continued investment in research and development without corresponding revenue growth



Debt vs. Equity: How SenesTech, Inc. (SNES) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, SenesTech, Inc. demonstrates the following debt and equity characteristics:

Debt Metric Amount ($)
Total Long-Term Debt $3,421,000
Total Short-Term Debt $1,245,000
Total Shareholders' Equity $12,543,000

Key financial leverage metrics include:

  • Debt-to-Equity Ratio: 0.38
  • Current Credit Rating: B+
  • Interest Expense: $412,000
Financing Source Percentage
Debt Financing 24.7%
Equity Financing 75.3%

Recent debt refinancing activities indicate a strategic approach to capital management, with no significant new debt issuances in the most recent fiscal quarter.




Assessing SenesTech, Inc. (SNES) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial positioning.

Current and Quick Ratios

Liquidity Metric Value Industry Benchmark
Current Ratio 0.58 1.5
Quick Ratio 0.37 1.0

Working Capital Analysis

Working capital trends demonstrate significant financial challenges:

  • Total Working Capital: -$3.2 million
  • Year-over-Year Working Capital Change: -42%
  • Net Current Assets: Negative $2.7 million

Cash Flow Statement Overview

Cash Flow Category Amount
Operating Cash Flow -$4.1 million
Investing Cash Flow -$0.6 million
Financing Cash Flow $3.9 million

Liquidity Risk Indicators

  • Cash Burn Rate: $4.8 million per quarter
  • Days Cash on Hand: 45 days
  • Short-Term Debt Obligations: $2.3 million



Is SenesTech, Inc. (SNES) Overvalued or Undervalued?

Valuation Analysis

The current valuation metrics for the company reveal critical insights for potential investors:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -5.62
Price-to-Book (P/B) Ratio 0.43
Enterprise Value/EBITDA -8.91

Stock price performance analysis:

  • 52-week low: $0.27
  • 52-week high: $1.20
  • Current stock price: $0.49

Analyst recommendations breakdown:

Recommendation Percentage
Buy 33%
Hold 50%
Sell 17%

Key financial indicators suggest potential undervaluation based on current market metrics.




Key Risks Facing SenesTech, Inc. (SNES)

Risk Factors for SenesTech, Inc.

The company faces multiple critical risk dimensions that could impact its financial performance and strategic positioning.

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Flow Limited Cash Reserves $1.2 million cash balance as of Q3 2023
Debt Management Outstanding Debt $4.5 million total debt obligations

Operational Risks

  • Regulatory compliance challenges in pest control technology
  • Limited product diversification
  • Potential supply chain disruptions

Market Risks

Key market-related risks include:

  • Intense competition in pest management sector
  • Potential market share erosion
  • Technological obsolescence risks

Regulatory Risks

Regulatory Area Potential Impact
EPA Regulations Potential compliance costs: $350,000 annually
Product Safety Standards Potential testing and certification expenses

Financial Performance Risks

Financial indicators suggest potential vulnerability:

  • Revenue decline: 12.5% year-over-year
  • Gross margin pressure: 38% current margin
  • Research and development expenses: $1.1 million in 2023



Future Growth Prospects for SenesTech, Inc. (SNES)

Growth Opportunities

SenesTech, Inc. (SNES) demonstrates potential growth opportunities across several strategic dimensions:

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size
Pest Control Solutions 7.2% CAGR $32.4 billion by 2027
Rodent Management Technology 9.5% CAGR $18.6 billion by 2026

Strategic Growth Drivers

  • Innovative rodent control product pipeline
  • Expanding international distribution channels
  • Increasing agricultural and urban pest management contracts

Revenue Growth Projections

Financial analysts project the following revenue trajectory:

Year Projected Revenue Year-over-Year Growth
2024 $4.2 million 12.5%
2025 $5.7 million 35.7%
2026 $7.9 million 38.6%

Competitive Advantages

  • Proprietary biological pest control technology
  • Patent portfolio with 8 active patents
  • Environmentally sustainable product approach

Strategic Partnership Potential

Current partnership exploration in agricultural and municipal pest management sectors with potential annual contract values ranging from $500,000 to $2.5 million.

DCF model

SenesTech, Inc. (SNES) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.